Glycotest Intellectual Property Portfolio Strengthened by Grant of Japanese Patent

Glycotest Inc., announced today that a Japanese patent has been granted that provides important protection of the Company’s core technology for early detection of life threatening liver disease.

Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis.  The Company’s mission is to reduce mortality and increase survival for the growing population at risk from serious liver diseases.  Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry.

The Japanese patent announced today joins five other patents previously granted in the United States and Australia which have been licensed exclusively and on a worldwide basis to Glycotest by Drexel University College of Medicine and the Blumberg Institute of the Hepatitis B Foundation, both in the Philadelphia area.  These patents cover the use of over 50 unique glycoprotein biomarkers for the diagnosis of liver cancers and other liver diseases.  In addition, the Company soon expects to announce positive developments in the patent protection of the proprietary assay technology required to measure these novel biomarkers.  Together these granted patents and the additional pending applications protect Glycotest’s proprietary liver disease diagnostic platform.

Commenting on these developments, Glycotest’s Chief Executive Officer Lawrence Cohen said, “The Glycotest patent portfolio is becoming substantial and we expect more good news in the coming year regarding our intellectual property position. Our IP portfolio along with the outstanding clinical results of our HCC Panel achieved to date are forming the base of what we expect to be a very strong company in liver disease diagnostics.”